Ixsys preclinical data

The Scripps Research Institute published findings with the LM609 antibody, which it has licensed to Ixsys (La Jolla, Calif.), showing disruption of angiogenesis in human tumors implanted into chick embryos.

Ixsys has humanized the antibody and expects to start clinical testing in the next 18 months for cancer and eye diseases such as macular degeneration and diabetic retinopathy. ...